Keros Therapeutics Files 8-K

Ticker: KROS · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1664710

Keros Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyKeros Therapeutics, Inc. (KROS)
Form Type8-K
Filed DateJan 10, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-filing, regulation-fd

TL;DR

Keros Therapeutics filed an 8-K on Jan 10, 2025, with corporate and financial updates.

AI Summary

Keros Therapeutics, Inc. filed an 8-K on January 10, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing details the company's corporate information, including its address at 1050 Waltham Street, Suite 302, Lexington, Massachusetts, and its IRS number 811173868.

Why It Matters

This 8-K filing serves as an official update from Keros Therapeutics, Inc. to the SEC, providing essential corporate and financial information to the public.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases or decreases risk.

Key Numbers

  • 001-39264 — SEC File Number (Identifies the company's filing with the SEC.)
  • 811173868 — IRS Number (Company's Employer Identification Number.)

Key Players & Entities

  • Keros Therapeutics, Inc. (company) — Registrant
  • January 10, 2025 (date) — Date of earliest event reported
  • 1050 Waltham Street, Suite 302 (address) — Principal executive offices
  • Lexington, Massachusetts (location) — Principal executive offices location
  • 02421 (zip_code) — Principal executive offices zip code
  • 811173868 (identifier) — IRS Employer Identification No.
  • 001-39264 (identifier) — SEC File Number

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, intended to disclose information under Regulation FD and to include financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on January 10, 2025.

What is Keros Therapeutics, Inc.'s principal executive office address?

The principal executive offices of Keros Therapeutics, Inc. are located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.

What is the company's SEC file number?

The SEC file number for Keros Therapeutics, Inc. is 001-39264.

What is the company's IRS Employer Identification Number?

The IRS Employer Identification Number for Keros Therapeutics, Inc. is 811173868.

Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-01-10 08:00:53

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 10, 2025, Keros Therapeutics, Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available through the Company's website and a copy is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation dated January 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: January 10, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.